Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04543539
Other study ID # IN.PACT™ AV Access PAS002
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 13, 2020
Est. completion date February 2029

Study information

Verified date February 2024
Source Medtronic
Contact PSR Study Team
Phone 763-526-5668
Email rs.productsurveillanceregistry@medtronic.com
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Long-term safety will be summarized


Description:

The purpose of this study is to evaluate the long-term safety of the IN.PACT™ AV Access Drug Coated Balloon (DCB) for treatment of subjects presenting with de novo or non-stented restenotic obstructive lesion of native arteriovenous dialysis fistulae (AVF) in the upper extremity. Patients will be followed for five years. The IN.PACT™ AV Access PAS 002 is required by the Food and Drug Administration (FDA) as a condition of product approval. This study is conducted within Medtronic's post market surveillance platform.


Recruitment information / eligibility

Status Recruiting
Enrollment 240
Est. completion date February 2029
Est. primary completion date February 2025
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility Primary Cohort Inclusion Criteria: - Patient is = 21 years of age - Patient has a mature native AV fistula created = 60 days prior to the index procedure - Patient has a de novo and/or non-stented restenotic lesion located between the arteriovenous anastomosis and axillosubclavian junction - Patient has a target lesion or a tandem lesion that is = 100 mm in length (by visual estimate) Note: Tandem lesions may be included provided they meet all of the following criteria: a. Separated by a gap of = 30 mm (3 cm), b. Total combined lesion length, including 30 mm gap, = 100 mm, c. Able to be treated as a single lesion - Patient has a target vessel diameter of 4.0 - 12.0 mm (by visual estimate) - Patient underwent successful crossing of the target lesion with the guide wire and pre-dilatation with a PTA balloon defined as: Residual stenosis of = 30% AND Absence of a flow limiting dissection or perforation AND No extravasation requiring treatment Primary Cohort Exclusion Criteria: - Women who are breastfeeding, pregnant, or are intending to become pregnant, or men intending to father children - Patient is receiving immunosuppressive therapy - Patient has an infected AV access or systemic infection - Patient with hemodynamically significant central venous stenoses that cannot be successfully treated prior to treatment of the target lesion - Patient with target lesion located central to the axillosubclavian junction - Patient has significant arterial inflow lesion requiring treatment more than 2 cm upstream from the anastomosis in the AV access - Patient has presence of pseudoaneurysm or aneurysm requiring treatment at the lesion site - Target lesion is located within a bare metal or covered stent - Patients with known allergies or sensitivities to paclitaxel - Patient with known contraindication, including allergic reaction, or sensitivity to contrast material that cannot be adequately pre-treated - Patient who cannot receive recommended antiplatelet and/or anticoagulant therapy - Patient is enrolled in another investigational drug, device, or biologic study and has not completed the primary endpoint, or was previously enrolled in this study - Patient has a co-morbid condition that, in the judgment of the Investigator, may cause him/her to be non-compliant with the protocol or confound the data interpretation - Patient has an active COVID-19 infection with ongoing sequela at enrollment or hospitalization for treatment of COVID-19 Inclusion Criteria for Extended Cohort: - Patient is = 21 years of age Exclusion Criteria for Extended Cohort: - Patient has an active COVID-19 infection with ongoing sequela at enrollment or hospitalization for treatment of COVID-19

Study Design


Intervention

Combination Product:
IN.PACT™ AV Drug Coated Balloon (DCB) - Primary Cohort
For the treatment of obstructive lesions up to 100 mm in length in the native arteriovenous dialysis fistulae with reference vessel diameters of 4 to 12 mm.
IN.PACT™ AV Drug Coated Balloon (DCB) - Extended Cohort
For treatment of stenosis in the AV circuit

Locations

Country Name City State
United States Albany Medical College Albany New York
United States University of Michigan Health System - University Hospital Ann Arbor Michigan
United States University of Virginia Medical Center Charlottesville Virginia
United States University of Iowa Iowa City Iowa
United States Lancaster General Hospital Lancaster Pennsylvania
United States Cedars-Sinai Heart Institute Los Angeles California
United States University of Wisconsin-Madison - Meriter Hospital Madison Wisconsin
United States NCH Healthcare System Naples Florida
United States Yale New Haven Hospital New Haven Connecticut
United States The Mount Sinai Hospital New York New York
United States MUSC Health Dialysis Access Institute Orangeburg South Carolina
United States Coastal Vascular and Interventional Pensacola Florida
United States FirstHealth of the Carolinas Pinehurst North Carolina
United States Oregon Health & Science University Hospital Portland Oregon
United States Mayo Clinic Rochester Minnesota
United States Spartanburg Regional Medical Center Spartanburg South Carolina
United States Stanford University Medical Center Stanford California
United States Staten Island University Hospital Staten Island New York
United States Holy Name Medical Center Teaneck New Jersey
United States Medstar Washington Hospital Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
Medtronic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Extended Cohort - Characterize Infections and Infestations Serious Adverse Events Characterize infections and infestations Serious Adverse Events, including pneumonia. Through 1-year and all-cause mortality through 5-years post-index procedure
Primary Infection and Infestations Serious Adverse Events Demonstrate Infection and Infestations Serious Adverse Events, including pneumonia, meets the performance goal of 30% in the primary cohort. Through 12 months post-index procedure
Secondary Mortality Rate Determine mortality rate Through 1, 2, 3, 4, and 5 years post-index procedure
See also
  Status Clinical Trial Phase
Recruiting NCT05302505 - Simulation-based Training for Nurses and Arteriovenous Fistula Puncture in Chronic Hemodialysis Patients N/A
Terminated NCT01642459 - The Outcomes of Arteriovenous Fistula Cannulated From Different Direction. N/A
Recruiting NCT04017806 - Investigating the Role of Luminal Pressure on Arteriovenous Fistula Maturation
Terminated NCT03668002 - Trial of Fistula Versus Graft in Elderly Patients N/A
Completed NCT06199609 - Changes in Cardiac Structure and Function After Establishment of Autologous Arteriovenous Fistula
Recruiting NCT04034433 - Exercise Program for Arteriovenous Fistula Maturation N/A
Active, not recruiting NCT04629118 - Intervention With Selution SLR™ Agent Balloon for Endovascular Latent Limus Therapy for Failing AV Fistulas (ISABELLA) Trial
Recruiting NCT02913365 - Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis N/A
Recruiting NCT05616104 - FLEX FIRST Registry Research Protocol
Recruiting NCT03886116 - Effect of Pre-operative Forearm Exercises on Arterial Venous Fistula Maturation and Blood Flow N/A
Completed NCT02513303 - Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes Phase 3
Completed NCT01863914 - Vascular Protective Effect of Rosuvastatin in Arteriovenous Fistula Phase 2
Recruiting NCT06001827 - SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study N/A
Completed NCT05326321 - Effect of Virtual Reality Glasses in The Arteriovenous Fistule Cannulation Processon Paın and Patient Satisfaction N/A
Recruiting NCT03741985 - Effect of Dumbbell Exercise on Arteriovenous Fistula in Patients With Hemodialysis N/A
Terminated NCT03566927 - FLEX®-DCB Dialysis ACCESS Stenosis Study N/A
Not yet recruiting NCT04393688 - Study Evaluating the Safety and Efficacy of Tri-wire Balloon for Treatment of Dysfunctional AV Fistula N/A
Recruiting NCT02447796 - Dexmedetomidine and Propofol As Sole Sedative Agent for Patients Undergoing Arteriovenous Fistula Surgery Phase 4
Terminated NCT01321866 - Cutting Balloon Versus Non-cutting Balloon for the Treatment of Venous Stenosis in the Fistulas of Hemodialyzed Patients N/A
Not yet recruiting NCT03137680 - Pre-Operative Forearm Exercise On Arteriovenous Fistula Mauration N/A